Background {#Sec1}
==========

Despite advances in the diagnosis and treatment of heart failure (HF), it still presents a major public health problem \[[@CR1]\], with increased incidence \[[@CR2], [@CR3]\] and poor prognosis \[[@CR4]--[@CR6]\]. In patients with HF and reduced left ventricular (LV) ejection fraction (HFrEF) several echo parameters correlated with functional capacity \[[@CR7]--[@CR16]\]. In contrast, in patients with HF and preserved LV EF (HFpEF), determinants of functional capacity are not well investigated \[[@CR15]--[@CR18]\]. Exercise capacity has been objectively assessed in the setting of HF using the six-min walk test (6-MWT) \[[@CR19]\]. While several echocardiographic markers at rest predicted limited exercise capacity in patients with HFrEF \[[@CR7]--[@CR16]\], none of them correlate with functional capacity in those with HFpEF \[[@CR15], [@CR17]\]. The aim of this study was to prospectively examine whether 6-MWT results correlate with cardiac function parameters in a consecutive group of patients with HF and to identify possible determinants of exercise capacity in those with HFpEF.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

We studied 111 patients (mean age 63 ± 10 years, 47% female), with clinical diagnosis of HF, and New York Heart Association (NYHA) functional class I-III, secondary to ischemic or non-ischemic etiology. Patients were referred to the Clinic of Cardiology, University Clinical Centre of Kosova, between May 2013 and June 2016. At the time of the study all patients were on optimum HF medications, optimized at least 2 weeks prior to enrollment, based on patient's symptoms and renal function: 82% were receiving ACE inhibitors or ARB, 78% beta-blockers, 12% calcium-blockers, 10% digoxin, 52% spironolactone, 62% diuretics. Patients with HFrEF had ischemic aetiology in 45%, hypertensive in 38%, and unknown aetiology in 17%. Patients with HFpEF had ischemic aetiology in 41% and hypertensive in 59%. All patients were in sinus rhythm. Patients with clinical evidence for cardiac decompensation, limited physical activity due to factors other than cardiac symptoms (e.g. arthritis), more than moderate mitral regurgitation, more than mild renal failure, chronic obstructive pulmonary disease or those with recent acute coronary syndrome, stroke or anemia were excluded. Patients gave a written informed consent to participate in the study, which was approved by the local Ethics Committee.

Data collection {#Sec4}
---------------

Detailed history and clinical assessment were obtained in all patients, in whom routine biochemical tests were also performed including hemoglobin, lipid profile, blood glucose level, and kidney function tests. Estimated body mass index (BMI) was calculated from weight and height measurements. Waist, hip measurements were also made and waist/hip ratio was calculated.

Echocardiographic examination {#Sec5}
-----------------------------

A single operator performed all echocardiographic examinations using a Philips Intelligent E-33 system with a multi-frequency transducer, and harmonic imaging as appropriate. Images were obtained with the patient in the left lateral decubitus position and during quiet expiration. Measurements of interventricular septal thickness, posterior wall thickness, and LV dimensions were made at end-diastole and end-systole, as recommended by the American Society of Echocardiography \[[@CR19]\]. LV mass (LVM) was calculated using the Devereux formula \[[@CR20]\] and normalized to body surface area (LV mass index \[LVMI\]).

LV volumes and EF were calculated from the apical 2 and 4 chamber views using the modified Simpson's method. Ventricular long axis motion was studied by placing the M-mode cursor at the lateral and septal angles of the mitral ring and the lateral angle of the tricuspid ring. Total amplitude of long axis motion was measured as previously described \[[@CR21]\] from peak inward to peak outward points. LV and right ventricular (RV) long axis myocardial velocities were also studied using Doppler myocardial imaging technique. From the apical 4-chamber view, longitudinal velocities were recorded with the sample volume placed at the basal part of LV lateral and septal segments as well as RV free wall. Systolic (s'), as well as early and late (e' and a') diastolic myocardial velocities were measured with the gain optimally adjusted. Mean value of lateral and septal LV velocities were calculated.

Left atrial diameter was measured from aortic root recordings with the M-mode cursor positioned at the level of the aortic valve leaflets. LA volumes were measured using area-length method from the apical four chamber views, according to the guidelines of the American Society of Echocardiography and European Association of Echocardiography \[[@CR22]\]. Left atrial maximal volume (LAV max) was measured at the end of LV systole, just before the opening of the mitral valve, LA minimal volume (LAV min) was measured at end diastole, right after mitral valve closure. LA emptying fraction (LA EF) was calculated with the formula \[[@CR22], [@CR23]\]:$$\documentclass[12pt]{minimal}
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Diastolic LV and RV function was assessed from filling velocities using spectral pulsed wave Doppler with the sample volume positioned at the tips of the mitral and tricuspid valve leaflets, respectively, during a brief apnea. Peak LV and RV early (E wave) and late (A wave) diastolic velocities were measured and E/A ratios were calculated. E wave deceleration time (DT) was also measured from peak E wave to the end of its deceleration in all study patients. The E/e' ratio was calculated from the transmitral E wave and the mean lateral and septal segments e' wave velocities. The isovolumic relaxation time was also measured from aortic valve closure to mitral valve opening, on the pulsed wave Doppler recording. LV filling pattern was considered 'restrictive' when E/A ratio was \>2.0, E wave deceleration time \< 140 ms and the left atrium dilated of more than 40 mm in transverse diameter \[[@CR24]\]. Total LV filling time was measured from the onset of the E wave to the end of the A wave and ejection time from the onset to the end of the aortic Doppler flow velocity.

Mitral regurgitation severity was assessed by colour and continuous wave Doppler and was graded as mild, moderate, or severe according to the relative jet area to that of the left atrium as well as the flow velocity profile, in line with the recommendations of the American and European Society of Echocardiography \[[@CR25], [@CR26]\]. Likewise, tricuspid regurgitation was assessed by colour Doppler and continuous-wave Doppler. Retrograde trans-tricuspid pressure drop \> 35 mmHg was taken as an evidence for pulmonary hypertension \[[@CR26], [@CR27]\]. All M-mode and Doppler recordings were made at a fast speed of 100 mm/s with a superimposed ECG (lead II).

Measurement of amino-terminal pro BNP {#Sec6}
-------------------------------------

Fasting venous blood was collected from study participants after they had rested in a supine position for 20 min. Samples were placed in disposable EDTA containers (1 g/L of plasma), and N-terminal proBNP was measured by a Cobas Elecsys E 411 analyzer (measuring range 5--35000 pg/mL) using a chemiluminescent immunoassay kit (Roche Diagnostics, Grenach-Wyhlen, Germany).

Six minute walk test {#Sec7}
--------------------

Within 24 h of the echocardiographic examination a 6-MWT was performed on a level hallway surface, administered by a specialized nurse who was blinded to the results of the echocardiogram. According to the method of Gyatt et al. \[[@CR28]\] patients were informed of the purpose and protocol of the 6 MWT which was conducted in a standardized fashion while patients on their regular medications \[[@CR29], [@CR30]\]. A 15 m flat, obstacle-free corridor was used and patients were instructed to walk as far as they can, turning 180° after they have reached the end of the corridor, during the allocated time of 6 min. Patients walked unaccompanied so not to influence walking speed. At the end of the 6 min the supervising nurse measured the total distance walked by the patient.

Using the norm-reference equation developed by Troosters \[[@CR31]\] for the prediction of 6MWT distance according to age, height, weight, and gender that has been proposed for healthy patients, we derived the percentage of the predicted value (PPV). PPV is computed by dividing the actual 6MWT distance by the expected value of 6MWT distance and then multiplying by 100. Troosters' equation is as follows: Predicted 6MWT distance = 218 + 5.14 ^∗^ height (cm) − 5.32 ^∗^ age (years) −1.8 ^∗^ weight (kg) + 51.31 ^∗^ sex (1--male, 0--female).

Statistical analysis {#Sec8}
--------------------

Data are presented as mean ± SD or proportions (% of patients). Continuous data was compared with two-tailed unpaired Student's *t* test and discrete data with Chi-square test. Correlations were tested with Pearson coefficients. Determinants of 6 MWT distance were identified with univariate analysis and multivariate logistic regression was performed using the step-wise method. A significant difference was defined as *p \<* 0.05 (2-tailed). Patients were divided according to their ability to walk \>300 m into good and limited exercise performance groups \[[@CR30]\], and were compared using unpaired Student *t*-test. Also, patients with HFpEF (\>45%) were compared with those with HFrEF (\<45%) using unpaired *t*-test.

Results {#Sec9}
=======

Patients with Limited vs. Good 6 MWT performance (Table [1](#Tab1){ref-type="table"}) {#Sec10}
-------------------------------------------------------------------------------------

Table 1Patients with limited exercise vs. good exercise capacity (6-MWT distance)VariableAll patients6MWT \> 300 m6MWT ≤ 300 m*P* value(*n =* 111)(*n =* 70)(*n =* 41)Clinical and biochemical data Age (years)63 ± 1061 ± 1066 ± 90.008 Female (%)4741560.135 Smoking (%)31.530340.676 Diabetes (%)2820410.027 Arterial hypertension (%)69.468.670.70.835 Waist/hips ratio0.97 ± 0.060.96 ± 0.060.98 ± 0.050.064 BMI (kg/m^2^)28.6 ± 4.128.7 ± 4.228.4 ± 3.80.764 BSA (m^2^)1.13 ± 0.21.15 ± 0.11.08 ± 0.10.067 Fasting glucose (mmol/L)6.8 ± 2.86.4 ± 2.47.9 ± 2.90.009 Total cholesterol (mmol/L)4.9 ± 1.24.9 ± 1.14.8 ± 1.20.439 Triglycerides (mmol/L)1.7 ± 0.71.7 ± 0.71.6 ± 0.80.747 Creatinine (μmol/L)96 ± 4698 ± 5693 ± 210.527 Hemoglobin (g/dl)12.7 ± 1.812.8 ± 1.612.3 ± 2.00.166 NT-ProBNP (pg/mL1178 ± 1635970 ± 12861534 ± 20720.124 Baseline heart rate (beats/min)74 ± 1671 ± 1580 ± 130.004Echocardiographic data Ejection fraction (%)47 ± 1548 ± 1445 ± 150.409 IVSd (cm)1.1 ± 0.21.1 ± 0.21.11 ± 0.10.923 Left atrium (cm)4.4 ± 0.84.2 ± 0.74.8 ± 0.90.001 LV EDD (cm)5.8 ± 1.05.7 ± 0.85.9 ± 1.10.319 LV ESD (cm)4.4 ± 1.24.2 ± 1.14.5 ± 1.30.281 Lateral MAPSE (cm)1.15 ± 0.41.2 ± 0.41.05 ± 0.30.051 Septal MAPSE (cm)1.0 ± 0.31.0 ± 0.30.9 ± 0.20.054 TAPSE (cm)2.15 ± 0.52.2 ± 0.42.1 ± 0.50.466 LVPWd (cm)1.05 ± 0.151.05 ± 0.21.05 ± 0.10.960 LVM (g)266 ± 85260 ± 75279 ± 1010.324 LVMI (g/m^2.7^)58 ± 2153 ± 1667 ± 260.006 E/A ratio1.05 ± 0.71.0 ± 0.71.1 ± 0.80.414 E wave DT174 ± 49178 ± 50167 ± 440.228 Filling time (ms)414 ± 132434 ± 141376 ± 1040.019 IVRT (ms)126 ± 41131 ± 42110 ± 340.037 PA acceleration time (ms)110 ± 24114 ± 23100 ± 210.006 E/e' ratio11 ± 5.910 ± 4.113 ± 8.00.053 Lateral e' (cm/s)6.1 ± 2.16.1 ± 2.46.0 ± 2.60.817 Lateral a'(cm/s)7.9 ± 3.68.1 ± 3.77.5 ± 3.50.461 Lateral s' (cm/s)5.3 ± 1.65.5 ± 1.54.9 ± 1.60.101 Septal e' (cm/s)4.9 ± 2.25.1 ± 2.24.6 ± 2.10.312 Septal a' (cm/s)7.15 ± 2.37.5 ± 2.46.4 ± 1.80.018 Septal s' (cm/s)4.4 ± 1.54.6 ± 1.64.0 ± 1.00.023 Right e' (cm/s)8.7 ± 3.08.9 ± 3.18.3 ± 2.70.305 Right a' (cm/s)12.5 ± 4.412.7 ± 4.311.8 ± 4.30.333 Right s' (cm/s)8.8 ± 3.09.8 ± 2.88.0 ± 3.20.086 LAV max (ml)73 ± 3568 ± 2680 ± 470.218 LAV min (ml)40 ± 2935 ± 2049 ± 380.067 LA EF (%)47 ± 1849 ± 1745 ± 160.314*LV* left ventricle, *EDD* end-diastolic dimension, *ESD* end-systolic dimension, *DT* deceleration time, *FT* filling time, *ET* Ejection time, *HR* heart rate, *IVSd* interventricular septum in diastole, *LVPWd* left ventricular posterior wall in diastole, *MAPSE* mitral annular plane systolic excursion, *TAPSE* tricuspid annular plane systolic excursion, *PA* pulmonary artery, *A* atrial diastolic velocity, *E* early diastolic filling velocity, *e'* early diastolic myocardial velocity, *s'* systolic myocardial velocity, *LA* left atrium, *LAV max* left atrial maximal volume, *LAV min* left atrial minimal volume, *LA EF* left atrial emptying fraction, *LVM* left ventricular mass, *LVMI* left ventricular mass index

Patients with limited exercise capacity were older (*p* = 0.008) and had higher prevalence of diabetes (*p* = 0.027) compared with those with good exercise capacity. Patients with limited 6-MWT had larger left atrium (*p* = 0.001), increased LVMI (*p* = 0.006), shorter LV filling time (*p* = 0.019), shorter isovolumic relaxation time (*p* = 0.037) and shorter PA acceleration time (*p* = 0.006), lower septal a' (*p* = 0.018) and s' (*p* = 0.023), compared to those with good 6-MWT performance. The rest of the clinical and echocardiographic indices were not different between groups.

Patients with HFpEF vs. HFrEF (Table [2](#Tab2){ref-type="table"}) {#Sec11}
------------------------------------------------------------------

Table 2Comparison of patients' data between patients HFpEF and HFrEFVariableHFpEFHFrEF*P* value(*n =* 55)(*n =* 56)Clinical and biochemical data Age (years)63 ± 6.862 ± 120.767 Body-mass index (kg/m^2^)29 ± 428 ± 3.60.130 Waist/hips ratio0.96 ± 0.060.96 ± 0.060.996 Fasting glucose (mmol/L)7.1 ± 3.16.7 ± 2.30.462 Total cholesterol (mmol/L)5.1 ± 1.14.7 ± 1.10.054 Triglycerides (mmol/L)1.8 ± 0.71.5 ± 0.70.137 Creatinine (μmol/L)87 ± 16105 ± 630.052 Hemoglobin (g/dL)12.8 ± 1.912.4 ± 1.50.078 Baseline heart rate (beats/min)70 ± 1579 ± 150.005 NT-ProBNP (pg/mL)681 ± 12801665 ± 18010.001 6-min walk distance (m)339 ± 106282 ± 1190.010 PPV of 6-min walk distance (%)56 ± 1945 ± 200.004Echocardiographic data IVSd (cm)1.1 ± 0.11.1 ± 0.20.666 Left atrium (cm)4.2 ± 0.84.6 ± 0.70.004 LV EDD (cm)5.2 ± 0.76.3 ± 0.9\<0.001 LV ESD (cm)3.5 ± 0.75.1 ± 1\<0.001 EDV (ml)135 ± 44213 ± 67\<0.001 ESV (ml)56 ± 8.7140 ± 52\<0.001 LV EF (%)59.6 ± 8.735 ± 7.5\<0.001 Lateral MAPSE (cm)1.27 ± 0.31.02 ± 0.40.001 Septal MAPSE (cm)1.14 ± 0.20.85 ± 0.2\<0.001 TAPSE (cm)2.3 ± 0.42.1 ± 0.50.062 LVPWd (cm)1.05 ± 0.21.06 ± 0.20.688 E/A ratio0.81 ± 0.31.3 ± 0.90.001 LVM (g)224 ± 69310 ± 77\<0.001 LVMI (g/m^2.7^)50 ± 1667 ± 23\<0.001 E wave DT189 ± 44159 ± 490.002 Filling time (ms)454 ± 147372 ± 990.001 IVRT (ms)122 ± 39130 ± 430.407 PA acceleration time (ms)118 ± 20101 ± 23\<0.001 E/e' ratio9.4 ± 4.713.5 ± 6.40.001 Lateral e' (cm/s)6.7 ± 2.65.3 ± 2.20.009 Lateral a' (cm/s)8.6 ± 3.37.1 ± 3.80.051 Lateral s' (cm/s)5.7 ± 1.34.8 ± 1.70.006 Septal e' (cm/s)5.7 ± 2.54.0 ± 1.1\<0.001 Septal a' (cm/s)7.9 ± 2.16.2 ± 2.0\<0.001 Septal s' (cm/s)4.9 ± 1.63.8 ± 0.9\<0.001 Right e' (cm/s)9.4 ± 3.27.9 ± 2.40.012 Right a' (cm/s)12.7 ± 4.512.2 ± 4.20.593 Right s' (cm/s)9.1 ± 3.18.3 ± 2.70.187  *LAV max*62 ± 2383 ± 570.005  *LAV min*29 ± 1851 ± 34\<0.001 LA EF (%)53 ± 1543 ± 180.012*LV* left ventricle, *EDD* end-diastolic dimension, *ESD* end-systolic dimension, *DT* deceleration time, *FT* filling time, *ET* Ejection time, *HR* heart rate, *IVSd* interventricular septum in diastole, *LVPWd* left ventricular posterior wall in diastole, *MAPSE* mitral annular plane systolic excursion, *TAPSE* tricuspid annular plane systolic excursion, *PA* pulmonary artery, *A* atrial diastolic velocity, *E* early diastolic filling velocity, *e'* early diastolic myocardial velocity, *s'* systolic myocardial velocity, *LA* left atrial, *LAV max* left atrial maximal volume, *LAV min* left atrial minimal volume, *LA EF* left atrial eemptying fraction, *LVM* left ventricular mass, *LVMI* left ventricular mass index, *PPV* percentage of the predicted value

The whole group of study patients walked a distance of 310 ± 116 m during 6-MWT. Patients with HFrEF walked significantly shorter distance compared those with HFpEF (*p* = 0.01, Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Six-minute walk test (6-MWT) distance in patients with heart failure and preserved ejection fraction (HFpEF) and in patients with heart failure and reduced ejection fraction (HFrEF)

Mean PPV of 6-MWT distance for the whole group was 50 ± 20%, and was lower in HFrEF compared to HFpEF patients (*p* = 0.004). Patients with HFrEF had lower hemoglobin (*p* = 0.007), higher baseline heart rate (*p* = 0.005), higher NT-ProBNP (*p* = 0.001), larger LAV max (*p* = 0.005), larger LAV min (*p \<* 0.001), larger LA (*p* = 0.004), increased LVM and LVMI (*p \<* 0.001, for both), shorter pulmonary acceleration time, lower septal s', e' and a' velocities, and lower septal and lateral mitral annular plane systolic excursion (MAPSE) (*p \<* 0.001 for all), higher E/A, shorter LVFT and higher E/e' (*p* = 0.001 for all), shorter E wave DT (*p* = 0.002), lower lateral e' (*p* = 0.009) and s' (*p* = 0.006), RV e' and LA EF (*p* = 0.012 for both) compared to HFpEF patients. Eleven of the 55 HFpEF patients and 23 of 56 HFrEF patients had mild-moderate mitral regurgitation. Seven of the 55 HFpEF patients and 17 of 56 HFrEF patients had mild or more tricuspid regurgitation.

Determinants of limited 6 MWT distance (Table [3](#Tab3){ref-type="table"}) {#Sec12}
---------------------------------------------------------------------------

Table 3Determinants of limited exercise in HF patientsVariableOR(CI 95%)*P* valueDeterminants of all HF study patients Univariate determinants  Age1.062(1.014--1.112)0.011  Diabetes mellitus0.353(0.150--0.892)0.017  NYHA class \>10.290(0.108--0.783)0.015  LVMI1.035(1.011--1.060)0.004  Left atrium2.410(1.404--4.137)0.001  E wave1.023(1.004--1.043)0.019  FT0.996(0.993--1.000)0.036  Heart rate1.039(1.010--1.069)0.008  PAAC0.972(0.952--0.993)0.010  E/e'1.092(1.009--1.181)0.028  Septal a'0.786(0.631--0.979)0.032  Septal s'0.661(0.444--0.984)0.041 Multivariate determinants  Left atrium diameter2.676(1.242--5.766)0.012  Diabetes mellitus0.274(0.084--0.898)0.033  Age1.067(0.999--1.140)0.052  NYHA class \>12.068(0.859--4.978)0.105  Gender0.406(0.122--1.350)0.141  E/e'1.043(0.943--1.153)0.415  FT0.997(0.989--1.005)0.463  Septal s'0.854(0.512--1.422)0.543  Heart rate1.011(0.940--1.088)0.764Determinants in HFpEF patients Univariate determinants  Diabetes mellitus0.276(0.082--0.926)0.037  Haemoglobin0.697(0.502--0.968)0.031  NYHA class \>10.206(0.043--0.993)0.049  BSA0.005(0.000--0.308)0.012  LVMI1.049(1.006--1.094)0.025  Lateral a'0.772(0.603--0.987)0.039  Lateral s'0.489(0.270--0.886)0.018 Multivariate determinants  Lateral s'0.295(0.099--0.882)0.029  Haemoglobin0.497(0.248--0.998)0.049  NYHA class \>10.051(0.003--1.034)0.053  BSA0.081(0.000--6.016)0.463  Lateral a'1.049(0.734--1.500)0.793  Age0.988(0.827--1.179)0.891  Diabetes0.860(0.109--6.786)0.886Determinants in HFrEF patients Univariate determinants  Age1.067(1.010--1.127)0.020  Left atrium3.236(1.333--7.856)0.009  LAV max1.021(1.001--1.042)0.045  LAV min1.029(1.003--1.055)0.032 Multivariate determinants  Age1.073(1.012--1.137)0.018  Left atrium diameter3.685(1.348--10.071)0.011  Gender2.147(0.556--8.288)0.268*BMI* body mass index, *BSA* body surface area, *NYHA* New York Heart Association, *LV* left ventricle, *EDD* end-diastolic dimension, *ESD* end-systolic dimension, *FT* filling time, *ET* ejection time, *PA* pulmonary artery, *A* atrial diastolic velocity, *E* early diastolic filling velocity, *e'* early diastolic myocardial velocity, *s'* systolic myocardial velocity, *LVMI* left ventricular mass index

### Determinants of limited 6 MWT distance in all HF patients {#Sec13}

High baseline heart rate (*p* = 0.008), age (*p* = 0.011), diabetes (*p* = 0.017) and NYHA class (*p* = 0.015) predicted limited 6-MWT distance. Also, enlarged LA (*p* = 0.001), increased LVMI (*p* = 0.004), increased E wave velocity (*p* = 0.019), short LV filling time (*p* = 0.036) and pulmonary artery acceleration time (*p* = 0.01), raised E/e' (*p* = 0.028), low septal a' and s' (*p* = 0.032 and *p* = 0.041, respectively), predicted limited 6 MWT distance. In multivariate analysis \[odds ratio 95% confidence interval\], only enlarged LA diameter \[2.676 (1.242--5.766), *p* = 0.012\], and diabetes \[0.274 (0.084--0.898), *p* = 0.033\], independently predicted the limited 6-MWT distance.

### Determinants of limited 6 MWT distance in HFpEF patients {#Sec14}

In univariate analysis, body surface area - BSA (*p* = 0.012), low hemoglobin level (*p* = 0.031), diabetes (*p* = 0.037), and NYHA class \> 1 (*p* = 0.049), increased LVMI (*p* = 0.025), low lateral s' (*p* = 0.018) and a' (*p* = 0.039) predicted limited 6-MWT distance. In multivariate analysis, lateral s' \[0.295 (0.099--0.882), *p* = 0.029, Fig. [2](#Fig2){ref-type="fig"}\], and hemoglobin level \[0.497 (0.248--0.998), *p* = 0.049\], independently predicted the limited 6-MWT distance.Fig. 2Systolic myocardial velocity (s') of the lateral left ventricular wall in patients with limited vs. good performance exercise capacity in patients with heart failure and preserved left ventricular ejection fraction

### Determinants of limited 6 MWT distance in HFrEF patients {#Sec15}

In univariate analysis, age (*p* = 0.02) and enlarged LA (*p* = 0.009) predicted limited exercise distance, which also remained as independent determinants in multivariate analysis: age \[1.073 (1.012--1.137), *p* = 0.018\] and LA diameter \[3.685 (1.348--10.071), *p* = 0.011, Fig. [3](#Fig3){ref-type="fig"}\].Fig. 3Left atrium diameter in patients with good vs. limited performance exercise capacity in patients with heart failure and reduced left ventricular ejection fraction

Discussion {#Sec16}
==========

Findings {#Sec17}
--------

The results of this study show that in general HF patients with limited exercise capacity are older and have worse left ventricular function and raised filling pressures than those with satisfactory exercise performance. However, determinants of exercise capacity differed significantly according to ejection fraction. While patients with reduced ejection fraction have the enlarged left atrium and advanced age as the independent determinants of exercise capacity, it was the low hemoglobin and reduced lateral s' the respective determinants in those with preserved ejection fraction.

Data interpretation {#Sec18}
-------------------

Patients with heart failure due to reduced ejection fraction are known to have worse segmental and overall ventricular function, with additional signs of myocardial stiffness and raised filling pressures in many of them \[[@CR32]\]. These perpetual changes result in left atrial enlargement due to the raised pressure, either because of venous hypertension, additional mitral regurgitation or the combination of both \[[@CR33]\]. Indeed left atrial enlargement has previously been shown to be the most important prognostic marker in heart failure patients, irrespective of the development of atrial fibrillation \[[@CR34]\]. It has also been taken as a reflection of the severity of LV myocardial stiffness, which is an end-stage dysfunction, thus an irreversible damage. On the other hand, many factors contribute to the pathophysiology of heart failure with preserved ejection fraction \[[@CR35]\], including atrial fibrillation, hypertension and kidney disease. Although none of our patients was in atrial fibrillation, the low hemoglobin levels were the main determinant of compromised exercise capacity. This reflects the need for acknowledging differences in the strategic management of these patients when compared with those of HFrEF. Finally, our findings discard ejection fraction, as the commonest marker of ventricular function as a determinant of exercise capacity.

### Limitations {#Sec19}

The main limitation of our study is that we did not investigate the response of echocardiographic measurements to exercise, at the time of symptoms development. However the objective of this study was to determine determinants of ordinary walking exercise limitation rather than heavy exercise in HF patients. The other limitation was the lack of invasive measurements of left atrial pressures, but the study was based on Doppler measurements which have been shown to be reproducible and correlate closely with invasive pressure measurements \[[@CR36]\]. The small sample size was another limitation, but we believe that future studies with larger sample size should strength our findings.

### Clinical implications {#Sec20}

Patients with HF have significantly limited exercise tolerance. Although ejection fraction is considered as the most useful index of LV function and the corner stone for recruiting patients for various treatment modalities, the other echo parameters should be considered as part of the conventional protocol of the follow-up of such patients, depending on overall LV systolic function: enlarged left atrium in HFrEF and impaired longitudinal systolic shortening and reduced hemoglobin in those with HFpEF. While management of patients with HFrEF could be standardized, and follow one protocol, that of patients with HFpEF is likely to be individualized.

Conclusions {#Sec21}
===========

In HF patients determinants of exercise capacity differ according to severity of overall LV systolic function, with left atrial enlargement in HFrEF and longitudinal systolic shortening and low hemoglobin in HFpEF as the the main determinants.
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